*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# The United Laboratories International Holdings Limited
# 聯邦制藥國際控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*
(Stock Code: 3933)

## APPROVAL FOR CLINICAL TRIAL OF THE GROUP'S PRODUCT UBT48128 TABLETS (OVERWEIGHT OR OBESITY)

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the application for the clinical trial of UBT48128 Tablets, a Class 1 new drug self-developed by The United Bio-Technology (Hengqin) Co., Ltd., a wholly-owned subsidiary of the Company, on indication of overweight or obesity has been approved by China National Medical Products Administration with reference numbers CXHL2601252, CXHL2601253 and CXHL2601254.

UBT48128 Tablets are small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. Through multiple mechanisms, including promoting insulin secretion, regulating appetite and modulating energy metabolism, once-daily oral administration helps lower blood glucose levels and reduce body weight, potentially improving patient adherence to treatment. Preclinical studies in multiple animal models show that UBT48128 significantly reduces body weight, with weight-loss effects superior to those of the control groups. The product is expected to demonstrate promising therapeutic potential and offer a new treatment option for patients who are overweight or obese.

UBT48128 Tablets have been approved by the U.S. Food and Drug Administration ("FDA") for an Investigational New Drug (IND) application on 11 August 2026.

Moving forward, the Company will continue to advance the research and development of new products, strengthen its competitiveness and innovation in the biopharmaceutical industry, and focus on chronic disease treatment by delivering higher-quality products and a robust pipeline to serve clinical practice and benefit patients, which is expected to generate greater value for the Company and its shareholders.

By Order of the Board
**The United Laboratories International Holdings Limited**
**Tsoi Hoi Shan**
*Chairman*

Hong Kong, 19 November 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.